Principal Financial Group Inc. Purchases 1,497 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Principal Financial Group Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDXFree Report) by 13.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,848 shares of the biopharmaceutical company’s stock after purchasing an additional 1,497 shares during the period. Principal Financial Group Inc.’s holdings in Celldex Therapeutics were worth $354,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CLDX. Allspring Global Investments Holdings LLC increased its stake in shares of Celldex Therapeutics by 77.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 496 shares in the last quarter. Point72 Hong Kong Ltd increased its stake in Celldex Therapeutics by 57.9% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 511 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Celldex Therapeutics by 604.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,869 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Celldex Therapeutics by 78.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 1,226 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Celldex Therapeutics in the 2nd quarter worth $135,000.

Celldex Therapeutics Stock Down 1.2 %

CLDX opened at $37.59 on Tuesday. The firm has a 50-day simple moving average of $37.72 and a two-hundred day simple moving average of $31.47. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $47.91. The company has a market capitalization of $1.78 billion, a PE ratio of -14.24 and a beta of 1.41.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CLDX. Cantor Fitzgerald cut their price target on Celldex Therapeutics from $54.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, November 3rd. TD Cowen assumed coverage on Celldex Therapeutics in a research note on Wednesday, December 20th. They issued an “outperform” rating for the company. HC Wainwright increased their price objective on shares of Celldex Therapeutics from $73.00 to $80.00 and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from an “underweight” rating to an “equal weight” rating and set a $27.00 price objective for the company in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $53.00.

Get Our Latest Research Report on CLDX

Celldex Therapeutics Company Profile

(Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

Featured Articles

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDXFree Report).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.